Focus Partners Advisor Solutions LLC Boosts Holdings in Medpace Holdings, Inc. $MEDP

Focus Partners Advisor Solutions LLC raised its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 24.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,592 shares of the company’s stock after acquiring an additional 1,105 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Medpace were worth $3,141,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Waddell & Associates LLC boosted its stake in shares of Medpace by 62.6% during the 4th quarter. Waddell & Associates LLC now owns 1,455 shares of the company’s stock worth $817,000 after purchasing an additional 560 shares during the last quarter. Cerity Partners LLC boosted its position in shares of Medpace by 41.0% in the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after acquiring an additional 23,530 shares during the last quarter. LPL Financial LLC boosted its position in shares of Medpace by 39.8% in the fourth quarter. LPL Financial LLC now owns 36,837 shares of the company’s stock worth $20,689,000 after acquiring an additional 10,480 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Medpace by 158.6% in the fourth quarter. Franklin Resources Inc. now owns 299,472 shares of the company’s stock worth $168,198,000 after acquiring an additional 183,645 shares during the last quarter. Finally, Schulhoff & Co. Inc. boosted its position in shares of Medpace by 1.1% in the fourth quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock worth $1,237,000 after acquiring an additional 25 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Royal Bank Of Canada decreased their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Leerink Partners reduced their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a research report on Wednesday, February 11th. Truist Financial reduced their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research report on Wednesday, February 11th. Wall Street Zen cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target on the stock in a research report on Friday, February 13th. Four analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Medpace presently has an average rating of “Hold” and a consensus target price of $467.08.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares in the company, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Jesse J. Geiger sold 31,707 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the transaction, the president owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is currently owned by insiders.

Medpace Price Performance

MEDP stock opened at $466.79 on Wednesday. Medpace Holdings, Inc. has a 1-year low of $294.07 and a 1-year high of $628.92. The firm has a fifty day moving average price of $456.86 and a two-hundred day moving average price of $506.57. The firm has a market cap of $13.33 billion, a price-to-earnings ratio of 29.34, a PEG ratio of 2.32 and a beta of 1.18.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. During the same quarter in the previous year, the firm earned $3.67 earnings per share. The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.